NextCell Pharma AB (OSTO:NXTCL) FCF Margin % : -437.79% (As of Feb. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NextCell Pharma AB's Free Cash Flow for the three months ended in Feb. 2024 was kr-10.22 Mil. NextCell Pharma AB's Revenue for the three months ended in Feb. 2024 was kr2.33 Mil. Therefore, NextCell Pharma AB's FCF Margin % for the quarter that ended in Feb. 2024 was -437.79%.

As of today, NextCell Pharma AB's current FCF Yield % is -94.57%.

The historical rank and industry rank for NextCell Pharma AB's FCF Margin % or its related term are showing as below:

OSTO:NXTCL' s FCF Margin % Range Over the Past 10 Years
Min: -162257.14 Med: -1052.92 Max: -387.78
Current: -387.78

During the past 9 years, the highest FCF Margin % of NextCell Pharma AB was -387.78%. The lowest was -162257.14%. And the median was -1052.92%.

OSTO:NXTCL's FCF Margin % is ranked worse than
62.78% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs OSTO:NXTCL: -387.78

NextCell Pharma AB FCF Margin % Historical Data

The historical data trend for NextCell Pharma AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB FCF Margin % Chart

NextCell Pharma AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

FCF Margin %

Get a 7-Day Free Trial

-1,052.92

-553.91

-672.37

-731.83

-473.89

NextCell Pharma AB Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
FCF Margin %	Get a 7-Day Free Trial															-514.19	-480.49	-475.30	-235.56	-437.79

Competitive Comparison of NextCell Pharma AB's FCF Margin %

For the Biotechnology subindustry, NextCell Pharma AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCell Pharma AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's FCF Margin % falls into.

NextCell Pharma AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NextCell Pharma AB's FCF Margin for the fiscal year that ended in Aug. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Aug. 2023 )	/	Revenue (A: Aug. 2023 )
	=	-47.925	/	10.113
	=	-473.89 %

NextCell Pharma AB's FCF Margin for the quarter that ended in Feb. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	-10.218	/	2.334
	=	-437.79 %

NextCell Pharma AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB (OSTO:NXTCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

65G:Germany

Address

Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157

Website

http://www.nextcellpharma.com

NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB (OSTO:NXTCL) Headlines

No Headlines